Targeted Therapy Improves Long-Term Outcomes for Patients with Rare Mutations Driving Lung Cancer
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Press Release5 Minute ReadFeb | 10 | 2022
Toshi Shioda, MD, PhDMy primary interest is the use of PGCLCs for toxicological research to understand how exposure to chemicals or prescription drugs might affect human reproduction.
BOSTON – Human primordial germ cells (PGCs) are the early precursors of the eggs (oocytes) and sperm that are necessary to keep humankind alive and reproducing. Medical researchers attempt to study their function and development using models of these cells called human primordial germ-cell-like cells (PGCLCs).
Human PGCLCs have been developed in several research centers, including the laboratory headed by Toshi Shioda, MD, PhD, in the Center for Cancer Research at Massachusetts General Hospital (MGH) and Harvard Medical School.
Natural PGCs exist only in embryos. The models were created to overcome the ethical and technical barriers surrounding the use of human embryonic tissues in experiments.
“My primary interest is the use of PGCLCs for toxicological research to understand how exposure to chemicals or prescription drugs might affect human reproduction,” Shioda says.
He and his colleagues are using the cells to study in the lab how exposure of women to chemicals such as general anesthetic could introduce heritable changes that can then be passed on to future generations without creating DNA mutations. This process is known as epigenetic inheritance.
They are also using this model to investigate how PGCs become testicular cancer, the most common malignancy in boys and young men.
The catch is that hPGCLCs don’t survive long in the laboratory and quickly lose their germ-cell-like features unless they are carefully and painstakingly nursed along with the use of blood serum or added chemicals. And even when these special cells survive and grow in laboratory dishes, they tend to drift away from their germ-cell-like identity and become other types of cells.
But as Shioda and colleagues explain in the journal Stem Cell Reports, they have developed a method for maintaining hPGCLCs and their germ-cell-like functions in cell culture without the need for special handling, with the cells surviving and continuing to replicate for at least five months without losing their primordial germ-cell-like features.
Using these cells, they have successfully generated hPGCLCs that carry various genetic mutations linked to testicular cancer, and are working to create the first synthetic tumor model of human testicular cancer with defined genetic mutations to aid in research into cancer prevention and treatment.
The work was supported by gifts from the RICBAC Foundation and the Escher Fund for Autism as well as grants from the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of “America’s Best Hospitals.”
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Mass General Brigham has received a $50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research.
In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day-to-day function when compared with whole brain radiation.
Mass General Brigham study highlights the efficacy of proton therapy in reducing toxicity while enhancing outcomes for patients with lower grade gliomas compared to traditional radiotherapy.
Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, has received a transformative $35 million gift from Irving Oil to advance cancer care and enhance the patient experience.
A national clinical trial led by investigators at Mass General Brigham Cancer Institute has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations.